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 The incidence of cirrhosis in Iceland has been the
lowest among western countries.
 In this nationwide prospective study, all patients
diagnosed with cirrhosis of the liver in Iceland over
a period of 5 years were included.
 The incidence of cirrhosis had increased 3-fold
compared with a study 10 years earlier owing to
increased alcohol consumption, obesity, and hepatitis
C.
 With thorough investigations a specific cause for
cirrhosis could be found in 94% of patients.https://doi.org/10.1016/j.jhepr.2021.100282In a nationwide population-based study from Iceland,
including all patients diagnosed with cirrhosis of the
liver over a period of 5 years, we found the incidence
of new cases had increased 3-fold compared with a
previous study 20 years ago. The increase is attribut-
able to increased alcohol consumption, an epidemic of
diabetes and obesity, and infection with the hepatitis
C virus. Furthermore, we found that with thorough
investigations, a specific cause for cirrhosis could be
found in 94% of patients. Patients with cirrhosis
frequently die of liver cancer and other complications
related to their liver disease.
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Landspitali-National University Hospital of Iceland, Reykjavik, IcelandJHEP Reports 2021. https://doi.org/10.1016/j.jhepr.2021.100282Background & Aims: The incidence of cirrhosis in Iceland has been the lowest in the world with only 3 cases per 100,000
inhabitants. Alcohol consumption has almost doubled in Iceland from 1980 to 2016. Obesity has also risen and hepatitis C
virus has spread among people who inject drugs in Iceland. The aim of this study was to evaluate the effects of these risk
factors on the incidence and aetiology of cirrhosis in Iceland.
Methods: The study included all patients diagnosed with cirrhosis for the first time during 2010–2015. Diagnosis was based
on liver histology or 2 of 4 criteria: cirrhosis on imaging, ascites, varices, and/or elevated INR.
Results: Overall, 157 patients were diagnosed, 105 (67%) males, mean age 61 years. The overall incidence was 9.7 cases per
100,000 inhabitants annually. Alcohol was the only underlying cause in 48/157 (31%), non-alcoholic fatty liver disease
(NAFLD) in 34/157(22%), and alcohol and hepatitis C together in 23/157(15%) were the most common causes. Only 6% of
patients had an unknown cause of cirrhosis. Upon diagnosis, the median model for end-stage liver disease score was 11 (IQR
8–15), 53% were of Child-Pugh class A whereas 61 (39%) had ascites, 11% encephalopathy, and 8% variceal bleeding. In all, 25%
of deaths were from HCC and 25% from liver failure.
Conclusion: A major increase in incidence of cirrhosis has occurred in Iceland associated with increases in alcohol con-
sumption, obesity, and hepatitis C. In a high proportion NAFLD was the aetiology and very few had unknown cause of
cirrhosis. The highest death rate was from HCC.
Lay summary: In a nationwide population-based study from Iceland, including all patients diagnosed with cirrhosis of the
liver over a period of 5 years, we found the incidence of new cases had increased 3-fold compared with a previous study 20
years ago. The increase is attributable to increased alcohol consumption, an epidemic of diabetes and obesity, and infection
with the hepatitis C virus. Furthermore, we found that with thorough investigations, a specific cause for cirrhosis could be
found in 94% of patients. Patients with cirrhosis frequently die of liver cancer and other complications related to their liver
disease.
© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Liver cirrhosis, an end stage of multiple chronic liver disorders, is
a major health problem worldwide. The patterns and trends in
cirrhosis mortality and incidence are largely attributable to dif-
ferences and changes in the 3 major recognised causes of this
disease, that is HBV and HCV infection, alcohol consumption, and
non-alcoholic fatty liver disease.1 Incidence and mortality has
been decreasing in many southern European countries but on
the rise in eastern European countries and in the UK.2,3 MostKeywords: Cirrhosis; Aetiology of cirrhosis; Incidence of cirrhosis; Alcohol; NAFLD;
Hepatitis C.
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Published studies are almost only retrospective and often refer to
defined geographical areas such as cities.4 The incidence of
cirrhosis in Iceland has been the lowest among western coun-
tries. In a retrospective study for the time period of 1994–2003
the incidence was 3.3 patients per 100,000 inhabitants annu-
ally.5 The main reasons for the low incidence was considered
relatively low per capita alcohol consumption as well as low
prevalence and a late introduction of hepatitis C into the Ice-
landic i.v. drug use population.5 The incidence of cirrhosis has
been found to be more than 4–5 times higher in Sweden and
Norway5,6 and almost 10 times higher in Denmark.7
In recent years, a significant change in the epidemiology of
major risk factors for cirrhosis has occurred in Iceland. Per capita
alcohol consumption increased from 4.3 L per inhabitant older
than 15 years in 1980, to 7.5 L in 2016.8 Hepatitis C has become a
Research articlesignificant health problem9 and there is an increase in diabetes
and obesity.10
In a systematic review of the natural history studies of
cirrhosis by D’Amico et al.,11 ‘good’ quality studies were defined
by 5 major quality criteria: (a) inclusion of consecutive patients,
(b) relevant baseline patient characteristics (age/sex, aetiology of
cirrhosis, Child-Pugh and model for end-stage liver disease
[MELD] scores), (c) length of follow-up reported, (d) clinically
important variables for prognosis included, (e) number of deaths
reported. The current study set out to include all these major
quality criteria. Furthermore, the benefits of a population-based
approach and rigorous diagnostic work-up was intended to
improve the generalisability of the results and avoid bias. To our
knowledge, this is the first study of the incidence of cirrhosis
including the entire population of a country.
The aims of this study were to assess the incidence and
aetiology of cirrhosis in Iceland and to evaluate the prognosis of
cirrhosis with respect to different aetiologies.Materials and methods
Patients and inclusion criteria
This was a prospective study. Every patient diagnosed with
cirrhosis in Iceland (population of 330,000) from 1 March 2010
to 28 February 2015 were eligible and enrolled at the time of
diagnosis.
In Iceland, the majority of patients with advanced liver dis-
ease are diagnosed and/or managed at Landspitali-National
University Hospital of Iceland (LUH), Reykjavik, where at least
95% of patients with liver disease are hospitalised. Few patients
are diagnosed in Akureyri District Hospital. In rare exceptional
cases diagnosis was suspected in other institutions and these
patients were referred to the National University Hospital.
Patient recruitment/identification
A letter informing on the planned study was sent out at the
beginning of 2010 to gastroenterologists, general surgeons, ra-
diologists, and pathologists in Iceland. They were encouraged to
refer all patients suspected of cirrhosis to the study hepatologists
based at LUH. To further facilitate early referral to LUH hep-
atologists, and to ensure that patients were not missed, with
regular intervals, all patients receiving at least 1 diagnosis indi-
cating liver fibrosis or cirrhosis, chronic liver disease, or com-
plications possibly caused by cirrhosis (International
Classification of Diseases 10th edition) were identified by
searching electronic medical records and computerised diagnosis
databases on a regular basis during the study period to avoid
missing any recent diagnoses of cirrhosis. Pathology and autopsy
reports were also regularly searched and screened for cirrhosis.
Information on cause of death was obtained from medical re-
cords and, when the patients died outside the hospital, the Ice-
landic cause of death register.
Data collection
The majority of patients (143 [91%]) were interviewed by 1 of the
authors who are clinical hepatologists (SO, OMB, or ESB). The rest
were mainly seen in the other main hospital in Iceland, Akureyri.
Upon examination of referral history and medical records, each
patient was thoroughly evaluated to determine if they had pre-
viously received a diagnosis of cirrhosis. Information was ob-
tained on general health, history of liver diseases, risk factors for
liver disease such as diabetes, obesity, alcohol use, drug useJHEP Reports 2021(including i.v.), and family history of liver disease. Medications
were documented. For deceased patients who died shortly after
diagnosis in hospital, information was obtained from medical
records.
Findings from physical examination, such as height, weight,
BMI, and the presence of ascites (confirmed by ultrasound), he-
patic encephalopathy, or variceal bleeding at diagnosis were
recorded.
The following laboratory analyses were performed: complete
blood count, platelets, creatinine, bilirubin, alkaline phosphatase,
alanine aminotransferase, aspartate aminotransferase, gamma-
glutamyl transpeptidase, INR, albumin, serum iron, transferrin
iron-binding capacity, ferritin, anti-nuclear antibody, smooth
muscle antibody, anti-mitochondrial antibody, ceruloplasmin, a-
1-antitrypsin, HBsAg, anti-HBC core, and anti-HCV (HCV RNA if
positive). In addition, a blood sample was stored for a possible
later genetic study. All patients underwent imaging studies (ul-
trasound, computed tomography [CT] scans, magnetic resonance
imaging) and upper endoscopy was performed to evaluate the
presence of varices. Patients were divided into those with
compensated and decompensated cirrhosis. Compensated
cirrhosis was defined by absence of gastrointestinal bleeding,
ascites (confirmed by ultrasound or CT), jaundice (serum bili-
rubin >50 lmol/L, normal <25), or symptomatic encephalopathy
on physical examination. Decompensated cirrhosis was defined
as presence of any of these abovementioned complications.
Liver biopsies, undertaken when clinically indicated, mostly
in patients with Child Pugh A were examined by the same
experienced pathologist (J.G.J.).
The MELD score12 and Child-Pugh score13 were calculated.
All living patients signed an informed consent for participa-
tion in the study.
For a patient to be eligible in this study they had to fulfil
either (i) biopsy-proven cirrhosis or (ii) at least 2 of the following
4 criteria: medical imaging indicating cirrhosis, elevated INR, if it
could not be attributed to any other cause such as treatment
with vitamin K antagonists, ascites, or gastroesophageal varices
(that could not be attributed to any other cause).
In patients without history of excess alcohol consumption
(<14 units of alcohol per week for women and <21 for men), the
aetiology of cirrhosis was considered to be non-alcoholic fatty
liver disease (NAFLD) rather than cryptogenic if the following
criteria were fulfilled: (i) liver biopsy (at any point) demon-
strating fatty liver disease or (ii) without liver biopsy a history of
diabetes mellitus and/or BMI >−30 before cirrhosis diagnosis.
Exclusion of other specific aetiologies was also required to
categorise NAFLD as the aetiology of cirrhosis.
Patients could have more than 1 cause of cirrhosis. If a patient
with HCV also had a history of alcohol abuse, both disorders
were registered as the aetiology. The patients were followed for
the documentation of development of hepatocellular carcinoma
(HCC) and transplantation and death or to the end of September
2019. The study protocol did not include longitudinal follow-up
for development of other complications of cirrhosis.
Statistical analysis
Data were processed using Microsoft Office Excel 2013 (Micro-
soft Corporation, Redmond, WA, USA), R-project (R Foundation
for Statistical Computing, Vienna, Austria), and STATA version
13.1 (Stata Corporation, College Station, TX, USA). Results are
presented as means (SD) as well as medians and IQR for non-
normally distributed data, and other statistics with CIs.2vol. 3 j 100282
Table 1. Patient characteristics at the time of diagnosis.
Men Women Total
No. of patients, n (%) 105 (67) 52 (33) 157
Age, years mean (SD) 60.8 (14.6) 61.9 (15.4) 61.1 (14.9)
ALD vs. NALD 56.5 (10.7) vs. 65.6 (16.9) 63.6 (9.85) vs. 61 (17.5) 58 (11) vs. 63.6 (17.2)
Aetiology, n (%)
Alcohol 36 13 49 (31)
Alcohol + HCV 21 2 23 (15)
HCV 6 3 9 (6)
NAFLD 24 10 34 (22)
PBC 2 6 8 (5)
AIH 0 6 6 (4)
Other 10 9 19 (12)
Unknown 6 3 9 (6)
Ascites, n (%) 42 19 61 (39)
Variceal bleeding, n (%) 10 3 13 (8)
Hepatocellular carcinoma, n (%) 11 0 11 (7)
Any sign of decompensated cirrhosis, n (%) 48 (46) 30 (58) 78 (50)
Child-Pugh class, n (%)
A 55 24 79/148 (53)
B 31 16 46/148 (31)
C 16 7 23/148 (16)
MELD score, median (IQR) 11 (8–15) 10.3 (8–15.3) 11 (8–15)
AIH, autoimmune hepatitis; ALD, alcoholic liver disease; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NALD, non-alcoholic liver disease;
PBC, primary biliary cirrhosis.The incidence of cirrhosis was calculated per 100,000 person-
years, stratified by year of diagnosis and sex and the age-
standardised incidence was calculated using the 1976 European
standard population.14 We plotted the age-standardised inci-
dence over time.
For survival analysis, where death was the endpoint, we
calculated and plotted the non-parametric cumulative incidence
function (CIF) over time, unstratified, and stratified by aetiology
and sex. For the former, we fitted a null-model competing-risks
regression. We also plotted the CIF derived from the first
competing-risks regression analysis outlined below. This CIF was
evaluated at the means of the variables in the aforementioned
analysis and also presented by aetiology alcohol (vs. other), and
by sex.
If individuals did not reach the endpoint, they were censored
at the end of the study period; for individuals who underwent
transplantation, this was considered a competing risk from the
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Graphs by sex, with 95% confidence interval
Fig. 1. Age standardised rates for all patients on the right, for females on
the left, and males in the middle, during the study period.
JHEP Reports 2021adjusted for) a number of factors on the risk of death with
competing-risks regression analysis.15 The variables included in
the analysis were aetiology alcohol vs. other (non-alcoholic
aetiology), age, sex, and MELD score. We plotted the CIFs
mentioned above and performed a competing-risks regression
per each of the following: all individuals, and only individuals
with HCC (none had underwent liver transplantation). For non-
parametric CIF all 157 individuals were evaluated. For
competing risks regression analysis and adjusted CIF, 8 were
excluded individuals due to a lack of MELD score at diagnosis.
Thus, the analyzed groups and their corresponding observations
were: all individuals (n = 149), and those with HCC (n = 22).
Entry time was at diagnosis of cirrhosis for all individuals; in
the case of only individuals with HCC entry time was at diagnosis
of HCC. We tested the proportionality of subhazards assumption
by interacting the coefficients of the variables of the regressions
with time, which indicated that the competing-risks regressions
were adequate for all individuals, but indicated non-
proportionality for the regression of only individuals with HCC.
Following the guidelines by Lau et al.,16 when there was an
indication of non-proportionality this was acknowledged andTable 2. Other aetiologies of cirrhosis.
Men Women Total
Hepatitis B 2 2 4
Hemochromatosis 3 0 3
Methotrexate 1 1 2
Familial intrahepatic cholestasis 2 0 2
Cystic fibrosis 0 2 2
Amiodarone 1 0 1
AIH + PBC overlap 0 1 1
Budd-Chiari 0 1 0
Secondary biliary cirrhosis 0 1 1
Hepatitis B + Hepatitis C 1 0 1
PBC/PSC overlap 0 1 1
Total 10 9 19
AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing
cholangitis.
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CIF of HCC, stratified by sex, all individuals
Aetiology non-alcohol Aetiology alcohol
Females Males
Fig. 2. Non-parametric cumulative incidence function of developing HCC
from diagnosis of cirrhosis. The endpoint was developing HCC: death
without HCC and transplantation were considered competing events. The
curves are presented by (A) all individuals, unstratified (blue line); (B) all in-
dividuals, stratified by aetiology alcohol (red line) vs. other (blue line); (C) all
individuals, stratified by sex male (red line) and female (blue line). CIF, cu-
mulative incidence function; HCC, hepatocellular carcinoma.
Table 3. Causes of death.
Male Female Total
Liver failure 13 6 19 (25)
HCC 17 2 19 (25)
Variceal bleeding 2 0 2 (3)
Another malignancy 6 1 7 (9)
Infections 6 6 12 (16)
Other* 11 7 18 (23)
55 22 77
Data are presented as n or n (%). *Non-liver related death: cardiac arrest/myocardial
infarction (n = 7), brain/subdural haematoma haemorrhage (n = 3), kidney failure (n =
2), trauma (n = 2), toxic effects of alcohol (n = 1), Alzheimer’s disease (n = 1), Par-
kinson’s disease (n = 1), and unclear cause of death (n = 1). HCC, hepatocellular
carcinoma.
Research articlesubhazard ratios (SHRs) reported, as this is the weighted average
over the follow-up. In the current study, data are presented for
the whole nation of Iceland during the study period. We report
CIs if generalising these results to a supranational region17 (e.g.
the Nordic countries) could be considered.
Non-parametric CIF was plotted and calculated where HCC
was the endpoint (n = 14). If individuals did not reach the
endpoint, they were censored at the end of the study period;JHEP Reports 2021death without HCC and transplantation were considered
competing events. Entry time was at the diagnosis of cirrhosis.
Ethics
This study was approved by the Bioethics Committee of Iceland
(VSN-09-158) and Data Protection Authority of Iceland.
Results
Incidence
A total of 157 patients were diagnosed with cirrhosis during the
study period. Clinical characteristics of the patients are shown in
Table 1. The mean age was approximately 61 years and males
comprised two-thirds of the patients (Table 1). The overall age
standardised incidence rate for the study period was 9.5 per
100,000 person-years (95% CI, 8.0–11.0); 12.6 for males (95% CI,
10.1–15.1) and 6.6 for females (95% CI, 4.8–8.3). The incidence
was significantly higher during the first study year, 14.4 per
100,000 person-years but remained stable thereafter (Fig. 1).
Causes of cirrhosis
Alcohol was the most common cause of cirrhosis, alone (31%) or
in combination with hepatitis C (15%). NAFLD was found to be
the aetiology in 22% of cases and 20% hepatitis C of whom the
majority also had alcohol as a risk factor for cirrhosis (Table 1).
Alcohol and HCV were more common among males than females
(Table 1). More than 1 cause of cirrhosis was found among 24
patients. A variety of other causes of cirrhosis were observed of
whom hepatitis B was the most frequent of uncommon causes
(Table 2). The most common method of diagnosis was by liver
biopsy, which was undertaken in 77 patients (49%).
Presenting complications and stage of disease
The most common complication of cirrhosis at diagnosis was
ascites in 61 patients (39%) (Table 1). Of 148 patients with known
Child-Pugh class, approximately 50% were of class A, 31% class B,
and 16% class C (Table 1). The median MELD score was 11.9 with
no difference between males and females (Table 1).
HCC
At diagnosis of cirrhosis, 8 (5%) patients were concomitantly
diagnosed with HCC with an additional 14 patients diagnosed
during follow-up (3 patients within 3 months from the diagnosis
of cirrhosis) with a total of 22/157 (14%) with HCC. Among males,
19/105 (18%) had HCC compared with only 3/52 (6%) of females.
Risk of HCC was highest in patients with NAFLD-induced
cirrhosis occurring in 8/34 (24%) of patients. The risk of HCC
was relatively low in patients who had alcohol alone as a cause of4vol. 3 j 100282
Table 4. Subhazard ratios of death without liver transplantation from competing-risks regression analysis.
Subhazard ratio, all individuals n = 149 95% CI
Age 1.05 1.03–1.07
Cause (alcohol) 0.69 0.37–1.29
Male sex 2.75 1.52–5.01
MELD 1.19 1.12–1.26
Subhazard ratio, HCC individuals (non-proportional) n = 22 95% CI
Age 1.01 0.97–1.05
Cause (alcohol) 0.89 0.21–3.78
Male sex 1.75 0.26–11.77
MELD 1.15 0.90–1.46
HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease.cirrhosis, occurring in 4/49 (8%), and also in patients with alcohol
and HCV as a cause of cirrhosis (17%). Two of 3 patients with
haemochromatosis developed HCC. Of 22 patients with HCC, 19
(86%) died during follow-up. Cumulative risk of developing HCC
with death and liver transplantation as competing risks, from
cirrhosis diagnosis, was 0.074 at 5 years, as shown in Fig. 2.
Survival and causes of death
The median follow-up was 61 (IQR 14–84) months. Cumulative
incidence function (non-parametric) of death without liver
transplantation, at 1 year was 0.23, and 0.79, for all individuals,
and only individuals with HCC, respectively (Fig. S1A,B). A total
of 5 (3.2%) patients underwent liver transplantation at a median
13 (range 6–81) months following diagnosis. Approximately 68%
deaths were considered directly related to their liver disease,
such as because of liver failure, HCC, and variceal bleeding, or
indirectly because of infections (Table 3). Interestingly, 25% of
deaths were due to HCC (Table 3). We cannot exclude the pos-
sibility that some of the patients who died and had HCC also had
some degree of liver failure. None of the patients who died from
other causes as listed in Table 3 had HCC. Only 3% of patients died
from variceal bleeding. Men had higher (non-parametric) cu-
mulative incidence of death without liver transplantation than
women (Fig. S1E,F). Cumulative incidence (non-parametric) of
death without liver transplantation in alcoholic induced cirrhosis
and non-alcoholic induced cirrhosis were similar overall
(Fig. S1C,D).
A multivariate competing-risks regression analysis using
biochemical and clinical parameters found 4 factors with SHRs of
death without liver transplantation indicating worse prognosis.
These were age, non-alcoholic aetiology, male sex, and MELD
score (Table 4). The CIF of death without liver transplantation
derived from this competing risks regression analysis with these
4 factors is shown in Fig. 3. After adjustment, the CIF of death
without liver transplantation at 1 year was 0.18 and 0.81, for all
individuals and only individuals with HCC, respectively
(Fig. 3A,B). After adjustment, the cumulative incidence of death
without liver transplantation was higher for non-alcoholic
induced cirrhosis (Fig. 3C,D). After adjustment, men had higher
cumulative incidence of death without liver transplantation than
women (Fig. 3E,F).
These aforementioned results/SHRs of death without liver
transplantation indicate the direction of the effects on the risk,
but not their magnitudes as indicated previously.18 Also, when
looking at only individuals with HCC (Table 4), the SHRs for this
competing-risks regression change with time, (i.e. they are non-
proportional); the results reported are the weighted average
over follow-up.16JHEP Reports 2021Discussion
This nationwide study demonstrated a major increase in the
incidence of cirrhosis in Iceland. The dominating causes of
cirrhosis were alcohol, NAFLD, and hepatitis C. The current study
included all major quality criteria for ‘good’ natural history
studies of cirrhosis presented by D’Amico et al.11 In a systematic
review of natural history studies, only one of the 118 retro-
spective studies included fulfilled all these criteria.18
Incidence of liver cirrhosis
The crude incidence rate during the 5-year period 2010–2015
was 9.7 per 100,000 inhabitants which compares with a retro-
spective Icelandic study from 1994 to 2003 where the incidence
was only 3.3.5 The incidence was highest in the first year of the
study. It is likely that the increased awareness and knowledge
about cirrhosis following the widely disseminated information
on the study among colleagues, might have led to the identifi-
cation of more patients (who may have had signs of cirrhosis for
some time) during the first year. Therefore, the subsequent years
are likely to represent the true incidence more accurately.
Unfortunately, the data on the epidemiology of cirrhosis
globally are very limited. There are no nationwide databases on
the causes of cirrhosis and incidence. The limited statistics kept
by health authorities focus on hospital discharge registries and
cause of death registries. However, apart from the current study
few retrospective studies on incidence of cirrhosis have been
carried out recently, almost exclusively in the Nordic countries,
Sweden, Norway, and Denmark.4–7,19–21 In spite of the increase
over recent years, the incidence remains low in Iceland.
In retrospective studies from Gothenburg (1994–2003)5 and a
more recent study from southern Sweden (2001–2011) the
incidence was 15.3 and 14.1, respectively.19 Contrary to the re-
sults of the current study, no increase in incidence was observed
in Sweden.19–21 A study from Norway showed that the incidence
was 13 cases per 100,000 inhabitants annually between 1999
and 2004.6 Strikingly higher incidence of 33 was reported by a
study in the defined population of Funen, Denmark between
1996 and 2006.7 The incidence appears to be stable in Sweden
and Norway, whereas it is increasing in Iceland and Denmark.4
From the available data it can be concluded that significant dif-
ferences exist in the Nordic countries in the epidemiology of
cirrhosis. The drawback of all these previous studies is the
retrospective design. Other studies outside the Nordic countries
show that cirrhosis mortality has been decreasing in Southern
European countries such as Spain, Italy, and France and
increasing in many eastern European countries.2,3 In the UK
annual incidence rose by 25%, increasing from approximately 12
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Fig. 3. Cumulative incidence function of death without liver transplantation from CRR analysis of individuals with cirrhosis. CIF of death without liver
transplantationwas derived from a CRR analysis that included the variables age, aetiology alcohol vs. other, sex, and MELD severity. The CIF curve was evaluated at
the means of the variables in said analysis, and also presented by aetiology alcohol (vs. other) and by sex. Columns from left to right correspond to all individuals
(A,C,E), and only individuals with HCC (B,D,F). Rows from top to bottom correspond to: (A,B) CIF evaluated at the means of all the variables (blue line); (C,D) CIF
presented by aetiology alcohol (red line) vs. other (blue line) and at the means of the rest of the variables; (E, F) CIF presented by sex – male (red line) and female
(blue line) and at the means of the rest of the variables. The endpoint was death and transplantation was considered a competing event. None of HCC individuals
underwent transplantation. CIF, cumulative incidence function; CRR, competing-risks regression; HCC, hepatocellular carcinoma.
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that this increased incidence is related at least partly to increased
alcohol consumption. Previous studies on changes in incidence
and mortality from cirrhosis have demonstrated relationship
with trends in alcohol consumption.23 Per capita alcohol con-
sumption in Iceland has increased from 4.3 L per inhabitant older
than 15 years in 1980 to 7.5 L in 2016.8 The increase in the
incidence of cirrhosis in Iceland probably reflects not only
increased alcohol consumption, but also increases in other risk
factors such as HCV, obesity, and diabetes mellitus type II.
Aetiology of cirrhosis
Alcohol was the sole cause of cirrhosis in 31% of cases and in
combination with hepatitis C in 15%. Thus, alcohol was the cause
or an important contributing factor of cirrhosis in 46% of patients
in the current study compared with 32% in a previous study for
the period 1994–2003.5
A total of 32 (20.4%) patients had HCV infection, in the ma-
jority of cases this was in combination with alcohol as a cause of
cirrhosis. This is remarkably similar to the recent study from
southern Sweden where 21.7% of the patients had HCV.19 In a
previous Icelandic study only 3% of patients had HCV infection.5
The increasing importance of HCV as a cause of cirrhosis was to
be expected because of the late spread of the virus among people
who inject drugs in Iceland9,24 and the long incubation time from
infection to development of cirrhosis, generally 20–30 years.25
The combination of increased alcohol consumption and
increased prevalence of HCV during the same period in Iceland is
of a particular concern as alcohol is known to potentiate the risk
of cirrhosis among patients with HCV.25
NAFLD was the cause of cirrhosis in approximately 22% of
patients. In the previous retrospective Icelandic study only 5% of
patients were considered to have NAFLD.5 Only 3% and 4% of
patients were considered to have NAFLD as the cause of their
cirrhosis in studies on cirrhosis from Norway and Sweden,
respectively.6,17 Similarly, in a recent study from Germany only
approximately 1% of patients with cirrhosis were thought to have
NAFLD as the aetiology of cirrhosis.22 These differences are
probably explained by the prospective approach of the current
study, an increased awareness of NAFLD as a cause of cirrhosis,
and differences in definitions. In the Swedish study19 the aeti-
ology was categorised as NAFLD only if the clinicians set out the
diagnosis and in the German study only if steatosis was seen on
ultrasound with exclusion of other aetiologies.26 The missing
data and uncertainties of the medical history are among many
drawbacks of retrospective studies.19,26 In the current study,
predetermined criteria were used to assess this potential aeti-
ology incorporating both presence of steatosis and features of
metabolic syndrome. In the previous Icelandic study, 20% of
patients were categorised as ‘cryptogenic’5 and it is likely that a
significant proportion of these patients had NAFLD. However, the
main explanation for the increased incidence of NAFLD-
associated cirrhosis is probably the changing epidemiology of
the main risk factors in Iceland with an epidemic of obesity and
diabetes mellitus developing in recent years. In 1967 the prev-
alence of obesity (BMI >−30) was 9% among males and 11% among
females (age 45–64 years). In 2007 the prevalence was 27% and
23% among males and females, respectively. During the same
period the prevalence of diabetes has doubled among males and
increased by 50% among females.10 The results of the current
study are in line with other studies on the epidemiology of
NAFLD/non-alcoholic steatohepatitis (NASH) showing a large
increase in NAFLD-induced liver cirrhosis.27 NASH has beenJHEP Reports 2021shown to be the second leading aetiology of liver disease among
patients awaiting liver transplantation in the USA.28 It is
conceivable that alcohol as an aetiology might be overestimated
as the cause of cirrhosis in retrospective studies5–7,18–21,26,29 and
probably a large underestimation of NAFLD/NASH as the cause of
cirrhosis as the results of the current study suggest. Primary
biliary cirrhosis (PBC) was the cause of cirrhosis in 5% of the
patients of the present study which was almost twice as high
(2.6%) as the proportion in the recent Swedish cohort of patients
with cirrhosis.18 This is in line with a recent study showing that
the incidence and prevalence of PBC in Iceland is among the
highest in the world.30 By contrast, during the study period only
1 patient was reported to have primary sclerosing cholangitis
(PSC) in an overlap with PBC as a cause of cirrhosis. A recent
study showed a much lower incidence of PSC in Iceland31
compared with other Nordic countries, where the incidence of
PSC is among the highest worldwide.32,33 In the current study,
only 6% were found to have cryptogenic cirrhosis which is much
lower than in other cohorts with cirrhosis.5–7,18–21,26,29 This is
most likely because of thorough scrutinisation of potential aeti-
ologies and probably reflects the fact that most patients in other
previous cohorts with cirrhosis classified as cryptogenic are
attributable to NAFLD/NASH. Thus, it seems that if detailed
diagnostic criteria are used, very few patients have cryptogenic
cirrhosis.
Complications of the liver cirrhosis
Approximately 50% of patients were of Child-Pugh class A. This is
a relatively high proportion of Child-Pugh class A patients in a
cohort of patients with cirrhosis. By comparison, in a systematic
review of 118 studies of survival in cirrhosis, 29% corresponded
to Child-Pugh class A.11 Thus, it seems that after initiation of the
study, increased awareness about cirrhosis among physicians
may have led to earlier diagnosis and therefore a larger pro-
portion of patients who were of Child-Pugh class A. Thus, it
seems that in the current study, more patients have milder liver
disease at diagnosis and therefore diagnosed earlier than in
retrospective studies. At diagnosis, 78 (50%) patients had 1 or
more complication, most commonly ascites in 39% of cases. In
the Danish study 76% had a complication on presentation7 and
64% in the recent Swedish study.19 The incidence of HCC in Ice-
land has been reported to be among the lowest worldwide. In a
retrospective study the annual incidence during 1984–1998 was
only 1.08/100,000.34 In the current study, 12% of patients
developed this complication, which is similar to other cohorts
with cirrhosis.11 A recent study from Iceland, published in ab-
stract form, found a significant increase in HCC over time,
reflecting increased prevalence of cirrhosis in the country.35
Prognosis
The current study was not designed to assess the prognosis
associated with complications that develop over time in patients
with cirrhosis. The cohort was probably not large enough to have
sufficient power to assess the risks associated with decom-
pensating events in patients with cirrhosis that larger studies
have been able to do.18–21,26,29,36
During the study period until December 2019, 77 (49%) of
patients died, 53% as a result of the complications of the un-
derlying liver cirrhosis. Interestingly, only 2/77 (2.6%) died of
variceal bleeding which is much lower than in other recent co-
horts with cirrhosis.16,36–38 Patients with alcoholic aetiology had
a better prognosis than patients with non-alcoholic aetiology.7vol. 3 j 100282
Research articleWe do not have a clear explanation for this, but it is conceivable
that in patients who stop drinking alcohol liver injury can
improve, whereas patients with other aetiologies cannot
improve liver injury by lifestyle. Access to addiction treatment is
very good and free of charge in Iceland. However, the protocol of
the study did not include effects of abstinence treatment on
prognosis.
A total of 5 (3.2%) patients underwent liver transplantation,
which is similar to other cohorts with cirrhosis with similar
duration of follow-up.38 The increased incidence of cirrhosis in
Iceland in recent years has led to a significantly increased need
for liver transplantation from 2.4 transplantations per million
population in 1984–1996, 5.2 in 1997–2006, to 8.9 during
2007–2012.39
Conclusions
In summary, a major change in the incidence of cirrhosis was
observed in Iceland with a more than 3-fold increase over aJHEP Reports 2021period of <10 years compared with a previous study undertaken
from 1994 to 2003. The increase is mostly caused by the increase
in nationwide alcohol consumption and an epidemic of obesity
and diabetes as well as the late evolution of the HCV infection
among people who inject drugs. This study also demonstrates
that if thorough evaluation and detailed diagnostic criteria are
applied, very few patients have cryptogenic cirrhosis.
With the elimination efforts launched in Iceland with the
Treatment as Prevention for Hepatitis C (TraP HepC) program in
201640 a decrease in the incidence of cirrhosis caused by HCV is
expected. Iceland has historically had strict alcohol control pol-
icies. However, access has increased in recent years. The pros-
pects regarding disease burden from NAFLD are uncertain but is
likely to increase. With elimination of hepatitis C as a major
health threat, continued strict public health approaches in
alcohol policy and promotion of lifestyle changes to avoid
obesity, cirrhosis is in large part a preventable condition.Abbreviations
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